<DOC>
	<DOCNO>NCT02179151</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ZGN-440 ( beloranib ) obese adolescent adult subject Prader-Willi Syndrome .</brief_summary>
	<brief_title>Double-Blind , Placebo Controlled , Phase 3 Trial ZGN-440 ( Beloranib ) Obese Subjects With Prader-Willi Syndrome</brief_title>
	<detailed_description>Phase 3 , Randomized , Double-Blind , Placebo Controlled , Phase 3 Trial ZGN-440 ( Subcutaneous Beloranib Suspension ) Obese Subjects Prader-Willi Syndrome Evaluate Total Body Weight , Food-related Behavior , Safety Over 6 Months</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<criteria>Confirmed genetic diagnosis PraderWilli Syndrome Age 1265 Obesity Age 1217 : BMI ≥ 95th percentile age gender Age 1865 : BMI ≥27 ≤60 kg/m2 Subjects live group home ≥ 50 % time Recent use ( within 3 month ) weight loss agent include herbal medication Poorly control severe psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prader-Willi Syndrome</keyword>
	<keyword>Obesity</keyword>
	<keyword>Hyperphagia</keyword>
</DOC>